An immunology‑focused pharmaceutical company is seeking novel druggable targets and/or molecules that are involved in regulation of immunometabolism in inflammatory disease. Specifically, the team are looking to focus on targetable molecules with demonstrated involvement in human pathology (e.g. a role in pathways linked to disease).
Approaches of Interest:
- Approaches that dramatically alter the immune cell state (e.g. macrophage M1 to M2 transition, or Th1 to Treg transition)
- Targets that specifically express in immune cells
- Improved modulation of pathways...